About
This forum is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in cytokine signalling. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of cytokines and cytokine signalling, and its implications for clinical practice.
The programmes are free from commercial bias, and feature leading experts sharing their knowledge and experience in the form of video tutorials.
Breaking News
ACR 2023 - CSF coverage highlights the most relevant data on RA, PsA, and axSpA. Including our Preview Brochures highlighting key posters and oral presentations ahead of the congress.
Podcasts
Bimekizumab in treating bDMARD-naïve PsA & upadacitinib in treating csDMARD and bDMARD IR PsA
Publications
Long-term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis
Podcasts
CSF Author Interview: Dr. David Martin, 2023
Podcasts
AxSpA Podcast: Safety and Efficacy of Upadacitinib
Publications
Effects of 1-year Tofacitinib Therapy on Angiogenic Biomarkers in Rheumatoid Arthritis
Publications
Global, Regional, and National Burden of Other Musculoskeletal Disorders, 1990–2020, and Projections to 2050: A Systematic Analysis of the Global Burden of Disease Study 2021
Podcasts
Discussing Rheumatology: October 2023
Podcasts
EULAR Recommendations Podcast 2023 with Professor Peter Nash & Dr. Andreas Kerschbaumer
Podcasts
Author Interview: Professor Martin Bergman, 2023
Publications
Risk of Major Adverse Cardiovascular Events in Immune-Mediated Inflammatory Disorders on Biologics and Small Molecules: Network Meta-Analysis
Publications
Risk of Major Adverse Cardiovascular Events in Patients with Rheumatoid Arthritis Treated with Conventional Synthetic, Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drugs: Observational Data from the German RABBIT Register
Publications
Therapy with JAK Inhibitors or bDMARDs and the Risk of Cardiovascular Events in the Dutch Rheumatoid Arthritis Population
Publications
Bimekizumab Treatment in Patients With Active Axial Spondyloarthritis: 52-week Efficacy and Safety from the Randomised Parallel Phase 3 BE MOBILE 1 and BE MOBILE 2 Studies
Publications
Gender-specific Differences in Patients with Psoriatic Arthritis Receiving Ustekinumab or Tumour Necrosis Factor Inhibitor: Real-world Data
Publications
One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib
Podcasts
Upadacitinib treating bDMARD-IR PsA & Post-marketing surveillance of tofacitinib treating PsA & RA
Publications
Global, Regional, and National Burden of Rheumatoid Arthritis, 1990–2020, and Projections to 2050: a Systematic Analysis of the Global Burden of Disease Study 2021
Publications
Tofacitinib Efficacy and Safety in Patients With Ankylosing Spondylitis by Prior Biologic Disease-Modifying Antirheumatic Drug Use: A Post Hoc Analysis
Podcasts
Discussing Rheumatology: September 2023
Podcasts
AxSpA Podcast: The Efficacy and Safety of Ixekizumab & Tildrakizumab
Publications
Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry
Publications
Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis Refractory to Biologic Therapy: 1-year Results From the Open-label Extension of a Phase III Study
Publications
Anti-GM-CSF Otilimab Versus Tofacitinib or Placebo in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Conventional or Biologic DMARDs: Two Phase 3 Randomised Trials (contRAst 1 and contRAst 2)
Publications
Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice
Publications
Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from the Phase III, Randomised, Placebo-Controlled, Active Reference BE OPTIMAL Study
Publications
Anti-gm-csf Otilimab versus Sarilumab or Placebo in Patients with Rheumatoid Arthritis and Inadequate Response to Targeted Therapies: A Phase III Randomised Trial (contRAst 3)
Publications
Janus Kinase Inhibitor—Tofacitinib Associated with Pemphigus: An Analysis of the FDA Adverse Event Reporting System Data
Publications
Guselkumab Modulates Differentially Expressed Genes in Blood of Patients with Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Trials
Publications
Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses
Publications
A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of Tildrakizumab Efficacy and Safety in Patients with Active Ankylosing Spondylitis
Publications